Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Open in API
Filings indexed 416 across all filing types
Latest filing 2019-01-11 Board/Management Inform…
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Board Transition
Board/Management Information Classification · 98% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details the intended stepping down of the Non-Executive Chairman and a Non-Executive Director, which constitutes an announcement of changes in senior management/board composition. This directly matches the definition for Board/Management Information (MANG). Although it is an RNS filing, the specific content points more strongly to MANG than the general RNS fallback category.
2019-01-11 English
Final Results
Earnings Release Classification · 95% confidence The document explicitly states it contains the "FINAL RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2018 AND NOTICE OF ANNUAL GENERAL MEETING". It provides financial highlights (Revenue, Operating loss, Cash) and operational progress for the fiscal year, which strongly indicates an Annual Report or a summary thereof. However, the text also mentions: "Hard copies of the Company's Annual Report and Accounts for the year ended 30 September 2018 and Notice of Annual General Meeting will be posted to shareholders in due course." Furthermore, it states: "This announcement should be read in conjunction with, and is not a substitute for, the full Annual Report." This structure—presenting key results and announcing the AGM, while deferring the full report—is characteristic of an Earnings Release (ER) or a preliminary announcement that summarizes the full Annual Report (10-K). Since it covers the full year and includes the AGM notice, it is a hybrid. Given the comprehensive nature of the financial highlights and the explicit mention of 'Audited Results' and 'Annual Report and Accounts', it is primarily functioning as the primary release of the annual financial performance. The presence of the AGM notice suggests a strong link to AGM materials, but the core content is the annual financial results summary. Since the full 10-K is not attached (it says it will be posted later), and it contains detailed financial summaries, the best fit among the options that cover annual results is the Earnings Release (ER), as this is the initial announcement of the full-year performance, even though it is more detailed than a typical quarterly ER. Alternatively, because it explicitly mentions the 'Annual Report and Accounts' and the AGM, it could be argued as a combined announcement. Given the options, and the fact that it summarizes the full year's audited results, ER is appropriate for the results component, but the inclusion of the AGM notice and the fact that it is an RNS filing suggests it is an announcement related to the formal annual reporting cycle. Since it contains the full year's results summary, it is more than just an RPA. If the document were the full 10-K, the code would be 10-K. Since it is the announcement of the results and the AGM, and it is filed via RNS, it fits best as an Earnings Release (ER) summarizing the annual performance, or potentially a Regulatory Filing (RNS) if the ER category is reserved strictly for quarterly results. However, the content is clearly the annual results announcement. I will classify it as ER because it announces the 'FINAL RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2018'. The RNS number (0429K) confirms it is a regulatory filing, but ER is the specific content type. FY 2018
2018-12-11 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details the 'TOTAL VOTING RIGHTS' as of a specific date (30 November 2018), which is a mandatory regulatory disclosure under FCA rules. This type of general, time-sensitive regulatory announcement that doesn't fit a more specific category (like DIRS, DIV, or DVA) is best classified as a general Regulatory Filing, or RNS, as per the provided definitions and the document's source.
2018-12-03 English
Notice of results for year ended 30 Sept 2018
Report Publication Announcement Classification · 99% confidence The document is very short (2909 characters) and explicitly states that the company 'expects to announce its full year results for the year ended 30 September 2018 on Tuesday 11 December 2018.' It is not the results themselves, but an announcement about *when* the results will be published. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports. The presence of the RNS Number and the closing statement referencing RNS confirms it is a regulatory announcement, but RPA is more specific than the general RNS fallback.
2018-11-23 English
Collaboration into identifying diagnosis of Autism
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement from the London Stock Exchange's news service (RNS). The content describes a specific corporate event: Oxford BioDynamics Plc entering into a collaboration agreement for biomarker identification. This is a material, non-financial announcement that does not fit the definitions for 10-K, ER, IR, or specific financial actions (CAP, DIV, POS). Since it is a general regulatory announcement disseminated via RNS, and it is not a report itself (like an AR or IR), the most appropriate classification is the general regulatory filing category, RNS.
2018-11-12 English
OBD signs fifth collaboration agreement
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content describes a new collaboration agreement for biomarker development in immuno-oncology. This is a general corporate update that does not fit the specific categories like Earnings Release (ER), Annual Report (10-K), Director's Dealing (DIRS), or Dividend Notice (DIV). Since it is a formal announcement released through the RNS system and doesn't fit a more specific category (like M&A or Capital Change), the most appropriate classification is the general Regulatory Filings category, RNS.
2018-11-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.